Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 5/20 | 0.43 |
| ▸ | SLC9A5 | Q14940 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 3/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CHUK | O15111 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907506 | 0.88 | TDP1 (0.44) | PLAUSLC9A5ADORA2ATDP1 | |
| SCHEMBL21730378 | 0.88 | TDP1 (0.44) | PLAUSLC9A5ADORA2ATDP1 | |
| SCHEMBL21722893 | 0.85 | IDO1 (0.56) | PLAUIKBKBIDO1 | |
| SCHEMBL29907726 | 0.85 | PLAU (0.36) | PLAUSLC9A5IKBKBIDO1CYP1A2 | |
| SCHEMBL22551963 | 0.85 | PLAU (0.36) | PLAUSLC9A5IKBKBIDO1CYP1A2 | |
| SCHEMBL29907583 | 0.84 | HPGDS (0.50) | IKBKBADORA2AADORA2BADORA1KDM4E | |
| SCHEMBL29907684 | 0.84 | LMNA (0.51) | PLAUIKBKBADORA2AADORA2BADORA1 | |
| SCHEMBL21730350 | 0.84 | LMNA (0.51) | PLAUIKBKBADORA2AADORA2BADORA1 | |
| SCHEMBL22551970 | 0.84 | HPGDS (0.50) | IKBKBADORA2AADORA2BADORA1KDM4E | |
| SCHEMBL22579104 | 0.78 | MAPT (0.40) | PLAUSLC9A5ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115181092-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| CN-115181092-A | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-112279837-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-111747954-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| EP-3837250-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD (CN) | 2021-06-23 | — | — | EP | disclosed |
| CN-112279837-A | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2021-01-29 | — | — | CN | disclosed |
| US-10898481-B2 | Pyrazine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-26 | — | — | US | disclosed |
| CN-112055709-A | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| CN-111747954-A | Pyrazine compounds and uses thereof | 迪哲（江苏）医药有限公司 | 2020-10-09 | — | — | CN | disclosed |
| WO-2020035052-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10898481-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | PLAU 1079/4885SLC9A5 1543/4885IKBKB 4155/4885 |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | PLAU 1079/4885SLC9A5 1543/4885IKBKB 4155/4885 |
| US-11571420-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | PLAU 1079/4885SLC9A5 1543/4885IKBKB 4155/4885 |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | PLAU 1079/4885SLC9A5 1543/4885IKBKB 4155/4885 |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | PLAU 1079/4885SLC9A5 1543/4885IKBKB 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.